Federal officials in the United States are actively working to safeguard critical hospital supplies, particularly IV bags, from potential disruptions caused by Hurricane Milton. The hurricane poses a threat to another manufacturer of IV fluids whilst hospitals across the country are still grappling with disruptions due to flooding at a major factory in North Carolina.
B. Braun Medical, a medical manufacturer, has announced that they are collaborating with U.S. health authorities to relocate their inventory of IV bags to a secure facility away from their Daytona Beach, Florida plant, which was closed in anticipation of the storm. The company aims to resume manufacturing and shipping operations on Friday morning as stated by their spokesperson, Allison Longenhagen.
Following damage to Baxter International’s North Carolina plant, responsible for 60% of the country’s sterile intravenous (IV) fluids supply, several IV producers including Braun have been called upon to augment supplies. U.S. hospitals heavily rely on over 2 million IV bags daily to maintain hydration and distribute medicines. The aftermath of Hurricane Helene had necessitated hospitals to begin conserving supplies.
Experts monitoring the situation expressed optimism regarding Braun’s proactive measures in Florida, contrasting it with Baxter’s unforeseen predicament in North Carolina. The American Hospital Association has urged the Biden administration to take additional actions to alleviate the shortage, proposing measures such as declaring a national emergency and leveraging defense production authorities to prioritise IV production.
Health Secretary Xavier Becerra acknowledged the disruptions and assured that the government is working diligently to address the supply chain challenges. Various steps are under consideration, including temporary imports, extending product expiration dates, and engaging other U.S. plants to ramp up production. The FDA highlighted that certain IV fluids were already on the drug shortage list pre-Hurricane Helene, allowing hospitals to compound scarce supplies to meet demand.
Efforts to streamline regulatory processes for compounding pharmacies were also suggested to shorten the typically lengthy timeline for new product development. The U.S. government has in the past implemented similar strategies to tackle shortages in critical areas like baby formula and medical supplies during the COVID-19 pandemic.
The urgent need to secure IV supplies underscores the importance of swift and coordinated actions to mitigate disruptions and ensure continuity of essential healthcare services for patients nationwide.